

SMOKING CESSATION PRODUCTS PRIOR AUTHORIZATION FORM

- Please submit **all** requested documentation with this request. Incomplete documentation may delay the processing of this request.
- To review the prior authorization guidelines for Smoking Cessation products, please refer to the Medical Assistance Prior Authorization of Pharmaceutical Services Handbook Chapter – **Smoking Cessation** (accessible at: <http://www.dhs.pa.gov/provider/pharmacyservices/drugsrequiringclinicalpriorauthorization/index.htm>).
- These agents are also subject to quantity limits. If the requested quantity exceeds the limit, please submit supporting chart documentation (refer to Quantity Limits list at: <http://www.dhs.pa.gov/provider/pharmacyservices/quantitylimitslist/index.htm>).

| PRIOR AUTHORIZATION INFORMATION | | PRESCRIBER INFORMATION | |
|--------------------------------------|---|------------------------------|------------------|
| <input type="checkbox"/> New request | <input type="checkbox"/> Additional info (PA# _____) | # of pages in request: _____ | Prescriber name: |
| Name of office contact: | | Specialty: | |
| Contact's phone number: | | State license #: | |
| LTC facility contact/phone: | | NPI: | MA Provider ID#: |
| RECIPIENT INFORMATION | | Street address: | |
| Recipient Name: | | Suite #: | City/state/zip: |
| Recipient ID#: | DOB: | Phone: | Fax: |

CLINICAL INFORMATION

| | | | |
|--|---|---|---------------------------------------|
| Non-preferred medication requested: | | | |
| <input type="checkbox"/> NicoDerm CQ patch (OTC) | <input type="checkbox"/> Nicorette lozenge (OTC) | <input type="checkbox"/> Nicotrol NS nasal spray | <input type="checkbox"/> Zyban tablet |
| <input type="checkbox"/> Nicorette chewing gum (OTC) | <input type="checkbox"/> Nicorette Mini lozenge (OTC) | <input type="checkbox"/> Nicotrol cartridge inhaler | <input type="checkbox"/> _____ |
| Strength: | Dose/directions: | Quantity: | Refills: |
| Diagnosis (<i>submit documentation</i>): | | Dx code (<i>required</i>): | |

Complete section applicable to drug being requested.

Section A: Zyban requests

| | |
|---|---|
| 1. Has the Recipient tried and failed the preferred alternative Smoking Cessation product – bupropion SR 150 mg tablet (generic Zyban)? | <input type="checkbox"/> Yes – <i>submit all supporting documentation of drug regimen tried and treatment outcomes</i> <input type="checkbox"/> No |
| 2. Does the Recipient have any contraindications or intolerances to the preferred alternative Smoking Cessation product – bupropion SR 150 mg tablet (generic Zyban)? | <input type="checkbox"/> Yes – <i>submit all supporting documentation of medication name and associated intolerances and contraindications</i> <input type="checkbox"/> No |

Section B: All other requests

| | |
|---|---|
| 1. Has the Recipient tried and failed any of the preferred nicotine replacement products? <i>Check all that apply.</i> <input type="checkbox"/> nicotine gum (OTC) <input type="checkbox"/> nicotine lozenge (OTC) <input type="checkbox"/> nicotine transdermal patch (OTC) | <input type="checkbox"/> Yes – <i>submit all supporting documentation of nicotine replacement product(s) tried and treatment outcomes</i> <input type="checkbox"/> No |
| 2. Does the Recipient have any contraindications or intolerances to any of the preferred nicotine replacement products listed in question (1)? | <input type="checkbox"/> Yes – <i>submit all supporting documentation of medication name and associated intolerances and contraindications</i> <input type="checkbox"/> No |

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

| | |
|------------------------------|--------------|
| Prescriber Signature: | Date: |
|------------------------------|--------------|

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.